Head-to-head evidence
Inclisiran vs Recaticimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Inclisiran · Leqvio
Marketed by Novartis and partners
NCT03397121 · Phase 3 · completed
The trial randomly assigned 482 participants to double-blind inclisiran or placebo, with 242 receiving inclisiran and 240 receiving placebo. Both primary LDL-C comparisons were statistically significant in favor of inclisiran, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical outcome, supporting a moderate evidence grade.
Next expected readout: October 2026 · NCT05360446 (registry estimate)
Recaticimab
Developed by Jiangsu Hengrui Pharmaceuticals
NCT04849000 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 709 participants, using percentage change in LDL cholesterol as the primary measure. The sponsor reports statistically significant LDL reductions of 45 to 53 percentage points versus placebo across all three dosing regimens.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inclisiran's landscape · Recaticimab's landscape